Nano-Scale Drug Delivery Systems

Iranian pharmaceutical researchers have developed multiple nano-scale drug delivery platforms, including liposomal formulations, polymeric nanoparticles, and nano-emulsions for targeted cancer therapy and other applications. Several formulations have progressed to clinical use domestically, leveraging the country's strong nano-research base and pharmaceutical manufacturing capability. Universities including Tehran, Shahid Beheshti, and Isfahan have active nano-medicine research groups publishing in international journals.

Nano-drug delivery addresses a practical problem: improving the efficacy and reducing the side effects of existing drugs by controlling how, when, and where they release their active ingredients. For Iran's sanctions-constrained healthcare system, this is particularly valuable — it allows existing generic drugs to be reformulated for improved performance without requiring access to novel active pharmaceutical ingredients, which may be harder to source under trade restrictions.

The nano-drug delivery work sits at the intersection of Iran's two strong biotech domains (pharmaceuticals and nanotechnology), creating synergies that neither field would achieve alone. The commercial potential is significant for markets in the Middle East, Central Asia, and Africa where affordability is paramount. However, regulatory barriers to exporting pharmaceutical nano-products remain substantial, and most clinical validation has been domestic rather than through internationally recognized trials.